Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
about
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept CohortTreatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.Long-term safety of immunomodulators in pediatric inflammatory diseases.Tocilizumab for treating juvenile idiopathic arthritis.Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.Biologics in Pediatric Rheumatology: Quo Vadis?New frontiers in the treatment of systemic juvenile idiopathic arthritis.Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.Choice of biologic drug among children with juvenile idiopathic arthritis.Innovations and Challenges by Applying Sublingual Laser Blood Irradiation in Juvenile Idiopathic Arthritis
P2860
Q36183846-0AB4477D-A47E-4B81-9CC3-B45DD2343D7BQ36795982-B4EA3790-8720-435A-BE0B-F743359BCB40Q36909288-3AB778A2-262D-47BB-A187-562196C21EADQ37195338-B79C87B7-0CCF-4D0A-9E82-ECC2DDD5C7C3Q37436386-C6ECDDC5-A4DD-4780-9414-12413CDECA66Q38232338-F131417B-A8B9-457D-92F5-EE2563D77CB7Q38723988-A22C19FD-5038-4C57-81FD-646129ADBFE7Q38805990-C81FB372-4A9E-4769-AE08-3E17E953B2F5Q38866152-E981390A-DFCF-446E-A8B4-3707AC075E95Q39424746-9E36DF5E-F68A-45FE-90FF-65DCEF6400C6Q40242247-36A97E6D-3A57-4481-88CD-F0DA8D640346Q54573196-6DF3AFD2-3035-4975-AEE1-58499EFB16F0Q59044785-8E1C32C9-D1BD-45E2-857D-D7976AE6A6E2
P2860
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Trends in prescription of biol ...... iologics in Children Register.
@en
Trends in prescription of biol ...... iologics in Children Register.
@nl
type
label
Trends in prescription of biol ...... iologics in Children Register.
@en
Trends in prescription of biol ...... iologics in Children Register.
@nl
prefLabel
Trends in prescription of biol ...... iologics in Children Register.
@en
Trends in prescription of biol ...... iologics in Children Register.
@nl
P2093
P2860
P1476
Trends in prescription of biol ...... iologics in Children Register.
@en
P2093
Esther P A H Hoppenreijs
Femke H M Prince
Janneke Anink
Joost F Swart
Koert M Dolman
Lisette W A van Suijlekom-Smit
Marieke H Otten
Marinka Twilt
Marion A J van Rossum
Nico M Wulffraat
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204641
P407
P577
2014-03-18T00:00:00Z